ATON ANNOUNCES PARTNERSHIP BETWEEN ITS SUBSIDIARY INOVIEM SCIENTIFIC AND SWISS COMPANY ABC BIOPPLY IN PRECLINICAL ONCOLOGY
ATON SA (Euronext Growth – FR0004153930 – ALTAO) today announced a strategic partnership between its subsidiary Inoviem Scientific and Swiss company Abc Biopply AG, an expert in humanised 3D models.
Inoviem Scientific: unique expertise at the heart of this partnership
This partnership builds on the distinctive strengths of Inoviem Scientific, a pioneer in translational pharmacology, including:
- Direct access to fresh tumour biopsies from patients, guaranteeing unrivalled clinical representativeness;
- Its exclusive ‘Pharmacology on the Spot’ technology, which allows samples to be processed ex vivo as soon as they are surgically removed, thus preserving the integrity of the tumour microenvironment;
- Its proven expertise in bioanalysis and clinical studies, which ensures continuity between research and clinical practice.
Thanks to these differentiating assets, Inoviem Scientific is able to create the conditions for strong synergy with abc biopply and its proprietary 3D multi-organoid™ technology, paving the way for a new generation of preclinical services in oncology.
abc biopply’s proprietary technology makes it possible to create hundreds of miniaturised versions of patient organs in the laboratory, using healthy and diseased tissue.
A major step forward in bridging the gap between research and clinical practice
The new preclinical services offering resulting from this partnership will enable cancer treatments to be tested directly on human tissue in a physiologically relevant 3D environment.
This innovation provides a concrete response to the major challenge of preclinical research: improving translational predictability and reducing the failure rate when moving into advanced clinical phases.
Aton, a catalyst for synergies
By orchestrating this partnership, Aton is confirming its strategy of bringing together its companies and innovative partners around integrated and differentiating solutions.
“Inoviem Scientific has built a unique model, linking the clinic to the laboratory through its access to biopsies and its “Pharmacology on the Spot” technology. It is these strengths that make the partnership with abc biopply possible and perfectly illustrate Aton’s mission: to transform preclinical research to accelerate the development of new therapies,” said Léone Atayi, President and Chief Executive Officer of Aton.